Using an inducible Npc1 knockout model with tamoxifen (TAM)-inducible Cre recombinase (ERT2-Cre) in DEN-CCl4-induced HCC model, we confirmed that Npc1 deficiency for an eight-week period significantly reduced tumor burden, tumor number, and liver-to-body weight ratios (Fig. 7p–s and Supplementary Fig. 9r, s). The gene discussed is NPC1; the disease is hepatocellular carcinoma.